A Phase 1 interventional study of Mirikizumab in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-25.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare two different formulations of mirikizumab in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will also be collected. Participants will remain in the study for about 12 weeks, after receiving study drug.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 milligram (mg) of mirikizumab as reference formulation (100 mg/mL), 2 × 1-mL pre-filled syringe administered as a subcutaneous (SC) injection into the arm/thigh/abdomen on day 1.
Drug: Mirikizumab
200 mg of mirikizumab as test formulation (100 mg/mL), 2 × 1-mL pre-filled syringe administered as a SC injection into the arm/thigh/abdomen on day 1.
Drug: Mirikizumab
Reference and test formulations of mirikizumab administered as a SC injection.
Also known as: LY3074828
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab
PK: Cmax of mirikizumab was evaluated.
Time frame: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose
PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Mirikizumab
PK: AUC(0-inf) of mirikizumab was evaluated.
Time frame: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose
PK: Area Under the Concentration Versus Time Curve From Time Zero to t, Where t is the Last Timepoint With a Measurable Concentration (AUC[0-tlast]) of Mirikizumab
PK: (AUC\[0-tlast\]) of mirikizumab was evaluated.
Time frame: Predose on Day 1, Day 3, Day 5, Day 8, Day 11, Day 15, Day 22, Day 29, Day 43, Day 57, Day 71 and Day 85 postdose
| Milestone | 200 Milligram (mg) Mirikizumab (Reference): Arm | 200 mg Mirikizumab (Reference): Thigh | 200 mg Mirikizumab (Reference): Abdomen | 200 mg Mirikizumab (Test): Arm | 200 mg Mirikizumab (Test): Thigh | 200 mg Mirikizumab (Test): Abdomen |
|---|---|---|---|---|---|---|
| Started | 10 | 10 | 10 | 10 | 10 | 10 |
| Received at least 1 dose of study drug | 10 | 10 | 10 | 10 | 10 | 10 |
| Completed | 10 | 10 | 10 | 10 | 10 | 10 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 |
PK: Cmax of mirikizumab was evaluated.
| micrograms per milliliter (ug/mL) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) |
|---|---|---|
| Pharmacokinetics (PK): Maximum Concentration (Cmax) of Mirikizumab | 12.7 ± 48 | 11.6 ± 45 |
PK: AUC(0-inf) of mirikizumab was evaluated.
| ug*day/mL | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to Infinity (AUC[0-inf]) of Mirikizumab | 229 ± 56 | 209 ± 45 |
PK: (AUC\[0-tlast\]) of mirikizumab was evaluated.
| ug*day/mL | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) |
|---|---|---|
| PK: Area Under the Concentration Versus Time Curve From Time Zero to t, Where t is the Last Timepoint With a Measurable Concentration (AUC[0-tlast]) of Mirikizumab | 225 ± 56 | 206 ± 46 |
Collected over Up To 85 Days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 200 mg Mirikizumab (Reference): Arm | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| 200 mg Mirikizumab (Reference): Thigh | 0/10 (0%) | 0/10 (0%) | 2/10 (20%) |
| 200 mg Mirikizumab (Reference): Abdomen | 0/10 (0%) | 0/10 (0%) | 1/10 (10%) |
| 200 mg Mirikizumab (Test): Arm | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| 200 mg Mirikizumab (Test): Thigh | 0/10 (0%) | 0/10 (0%) | 0/10 (0%) |
| 200 mg Mirikizumab (Test): Abdomen | 0/10 (0%) | 0/10 (0%) | 3/10 (30%) |
| Event | 200 mg Mirikizumab (Reference): Arm | 200 mg Mirikizumab (Reference): Thigh | 200 mg Mirikizumab (Reference): Abdomen | 200 mg Mirikizumab (Test): Arm | 200 mg Mirikizumab (Test): Thigh | 200 mg Mirikizumab (Test): Abdomen |
|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 0/10 | 2/10 | 0/10 | 0/10 | 0/10 | 2/10 |
| HeadacheNervous system disorders | 0/10 | 1/10 | 0/10 | 0/10 | 0/10 | 2/10 |
| VomitingGastrointestinal disorders | 0/10 | 1/10 | 0/10 | 0/10 | 0/10 | 0/10 |
| NasopharyngitisInfections and infestations | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 | 1/10 |
| Foot fractureInjury, poisoning and procedural complications | 0/10 | 0/10 | 1/10 | 0/10 | 0/10 | 0/10 |
| AgeusiaNervous system disorders | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 | 1/10 |
| AnosmiaNervous system disorders | 0/10 | 0/10 | 0/10 | 0/10 | 0/10 | 1/10 |
All participants who received at least 1 dose of study drug.
| Age, Categorical(Participants) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 26 | 27 | 53 |
| >=65 years | 4 | 3 | 7 |
| Sex: Female, Male(Participants) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| Female | 19 | 22 | 41 |
| Male | 11 | 8 | 19 |
| Ethnicity (NIH/OMB)(Participants) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 |
| Not Hispanic or Latino | 30 | 29 | 59 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 1 | 1 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 29 | 29 | 58 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 200 mg Mirikizumab (Reference) | 200 mg Mirikizumab (Test) | Total |
|---|---|---|---|
| United States | 30 | 30 | 60 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Sep 2020 to primary completion in Jan 2021, 4 months.
Results were first posted in Jan 2024, 3 years after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab